Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics (Nasdaq: ATRA), a leader in T-cell immunotherapy, has granted 3,700 restricted stock units to a newly hired employee. This inducement grant, approved by the Compensation Committee and made under the company's 2018 Inducement Plan, is in accordance with Nasdaq Listing Rule 5635(c)(4). The grant date is September 3, 2024.
The restricted stock units have a four-year vesting schedule: 25% vests on the first quarterly vesting date after the first anniversary, with the remaining 75% vesting in 12 approximately equal quarterly installments over the following three years. Vesting is subject to continuous employment with Atara.
Atara Biotherapeutics (Nasdaq: ATRA), leader nell'immunoterapia con cellule T, ha concesso 3.700 unità di azioni riservate a un nuovo dipendente. Questa concessione di indennità, approvata dal Comitato di Compensazione e effettuata nell'ambito del Piano di Indennità 2018 dell'azienda, è in accordo con la Regola di Quotazione Nasdaq 5635(c)(4). La data di concessione è 3 settembre 2024.
Le unità di azioni riservate hanno un piano di maturazione di quattro anni: il 25% matura alla prima data di maturazione trimestrale dopo il primo anniversario, con il restante 75% che matura in 12 rate trimestrali circa uguali nei successivi tre anni. La maturazione è soggetta all'impiego continuo con Atara.
Atara Biotherapeutics (Nasdaq: ATRA), líder en terapia inmunológica con células T, ha otorgado 3,700 unidades de acciones restringidas a un nuevo empleado. Esta concesión por inducción, aprobada por el Comité de Compensación y realizada bajo el Plan de Inducción de 2018 de la empresa, está de acuerdo con la Regla de Cotización 5635(c)(4) de Nasdaq. La fecha de concesión es el 3 de septiembre de 2024.
Las unidades de acciones restringidas tienen un programa de consolidación de cuatro años: el 25% se consolida en la primera fecha trimestral de consolidación después del primer aniversario, con el 75% restante consolidándose en 12 cuotas trimestrales aproximadamente iguales durante los siguientes tres años. La consolidación está sujeta a la permanencia en el empleo con Atara.
아타라 생명과학(나스닥: ATRA), T세포 면역요법의 선두주자인 아타라가 신규 채용자에게 3,700개의 제한 주식 단위를 부여했습니다. 이 유인 보상은 보상 위원회의 승인을 받아 회사의 2018 유인 계획에 따라 이루어졌으며, 나스닥 상장 규정 5635(c)(4)에 부합합니다. 보상 부여일자는 2024년 9월 3일입니다.
제한 주식 단위의 4년 분할 일정은 다음과 같습니다: 첫 번째 기념일 이후 첫 분기 분할 날짜에 25%가 분할되고, 나머지 75%는 다음 3년 동안 약 12회의 동등한 분기 분할로 분할됩니다. 분할은 아타라와의 지속적인 고용에 따라 달라집니다.
Atara Biotherapeutics (Nasdaq: ATRA), un leader en immunothérapie à base de cellules T, a accordé 3 700 unités d'actions restreintes à un nouvel employé. Cette attribution incitative, approuvée par le Comité de Rémunération et réalisée dans le cadre du Plan d'Induction 2018 de l'entreprise, est conforme à la Règle de Cotation Nasdaq 5635(c)(4). La date d'attribution est le 3 septembre 2024.
Les unités d'actions restreintes ont un calendrier d'acquisition de quatre ans: 25% sont acquis à la première date d'acquisition trimestrielle après le premier anniversaire, les 75% restants étant acquis en 12 versements trimestriels à peu près égaux au cours des trois années suivantes. L'acquisition est soumise à l'emploi continu avec Atara.
Atara Biotherapeutics (Nasdaq: ATRA), ein führendes Unternehmen in der T-Zell-Immuntherapie, hat 3.700 eingeschränkte Aktieneinheiten an einen neu eingestellten Mitarbeiter gewährt. Dieser Anreiz wurde vom Vergütungsausschuss genehmigt und im Rahmen des Unternehmensplans von 2018 gewährt, und entspricht der Nasdaq-Listing-Regel 5635(c)(4). Das Gewährungsdatum ist der 3. September 2024.
Die eingeschränkten Aktieneinheiten haben einen vierjährigen Vesting-Zeitplan: 25% werden am ersten quartalsweisen Vesting-Datum nach dem ersten Jahrestag fällig, weitere 75% werden in 12 ungefähr gleichen quartalsweisen Raten in den folgenden drei Jahren vested. Das Vesting ist an eine kontinuierliche Beschäftigung bei Atara gebunden.
- Atara is attracting new talent with stock-based compensation
- The company is complying with Nasdaq listing rules for inducement grants
- None.
The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates.
Atara is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Atara Biotherapeutics, Inc.
Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of hematological malignancies and B-cell driven autoimmune diseases. Atara is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240906022551/en/
Investor and Media Relations:
Jason Awe, Ph.D.
Head of Corporate Communications & Investor Relations
(805) 217-2287
jawe@atarabio.com
Source: Atara Biotherapeutics, Inc.
FAQ
How many restricted stock units did Atara Biotherapeutics (ATRA) grant to the new employee?
What is the vesting schedule for the restricted stock units granted by Atara Biotherapeutics (ATRA)?
When is the grant date for the restricted stock units issued by Atara Biotherapeutics (ATRA)?
Under which plan did Atara Biotherapeutics (ATRA) grant the restricted stock units?
